Gossamer Bio
GOSS
127 hedge funds and large institutions have $533M invested in Gossamer Bio in 2022 Q2 according to their latest regulatory filings, with 18 funds opening new positions, 34 increasing their positions, 50 reducing their positions, and 26 closing their positions.
766% more call options, than puts
Call options by funds: $10.7M | Put options by funds: $1.23M
73% more capital inflows, than outflows
Capital inflows: $68.7M | Capital outflows: $39.7M
33% more funds holding in top 10
Funds holding in top 10: 3 → 4 (+1)
4.29% more ownership
Funds ownership: 78.3% → 82.59% (+4.3%)
9% less funds holding
Funds holding: 139 → 127 (-12)
31% less first-time investments, than exits
New positions opened: 18 | Existing positions closed: 26
32% less repeat investments, than reductions
Existing positions increased: 34 | Existing positions reduced: 50
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
Millennium Management
New York
|
+$10.1M |
| 2 |
Polar Asset Management Partners
Toronto,
Ontario, Canada
|
+$8.16M |
| 3 |
Point72 Asset Management
Stamford,
Connecticut
|
+$7.47M |
| 4 |
Woodline Partners
San Francisco,
California
|
+$6.38M |
| 5 |
Citigroup
New York
|
+$6.26M |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
OFM
Omega Fund Management
Boston,
Massachusetts
|
-$12.9M |
| 2 |
Jacobs Levy Equity Management
Florham Park,
New Jersey
|
-$5.32M |
| 3 |
Norges Bank
Oslo,
Norway
|
-$3.22M |
| 4 |
Marshall Wace
London,
United Kingdom
|
-$1.74M |
| 5 |
Parkman Healthcare Partners
Stamford,
Connecticut
|
-$1.74M |
GOSS Hedge Fund Activity: Q2 2022 in Review
127 of the 5,962 institutional investors tracked by Wall St. Rank reported a position in Gossamer Bio (GOSS) for Q2 2022, worth a combined $533M — up 2.6% from $520M a quarter earlier.
Sellers outnumbered buyers: 26 funds closed out of GOSS and 18 opened new positions — a net loss of 8 holders — while 50 trimmed existing stakes and 34 added.
The largest buyer was Millennium Management, adding an estimated $10.1M. The largest seller was Omega Fund Management, cutting an estimated $12.9M.
- 127 institutional investors held Gossamer Bio (GOSS) as of Q2 2022, down from 139 in Q1 2022.
- Funds reported $533M of Gossamer Bio stock for Q2 2022, up 2.6% quarter-over-quarter.
- 18 funds opened new Gossamer Bio positions in Q2 2022 and 26 closed out, a net change of -8 holders.
- The largest Gossamer Bio buyer in Q2 2022 was Millennium Management, an estimated $10.1M added.
- The largest Gossamer Bio seller in Q2 2022 was Omega Fund Management, an estimated $12.9M sold.
Based on aggregated 13F filings for Q2 2022.